Q1 EPS Forecast for Nektar Therapeutics Boosted by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright analyst A. He now expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.17). HC Wainwright has a “Buy” rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.68) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.87) EPS and FY2029 earnings at ($0.52) EPS.

A number of other brokerages have also recently issued reports on NKTR. B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price target for the company. Oppenheimer upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price for the company in a report on Friday. Finally, William Blair restated a “market perform” rating on shares of Nektar Therapeutics in a research note on Thursday, March 13th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Trading Up 1.4 %

Shares of NKTR stock opened at $0.91 on Monday. The company’s fifty day moving average price is $0.88 and its 200-day moving average price is $1.07. The stock has a market cap of $167.73 million, a PE ratio of -1.08 and a beta of 0.65. Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.33. The company had revenue of $29.18 million for the quarter, compared to analysts’ expectations of $36.65 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.

Insiders Place Their Bets

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now owns 326,904 shares in the company, valued at approximately $307,289.76. This represents a 13.52 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the sale, the insider now directly owns 351,892 shares in the company, valued at approximately $316,702.80. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 118,591 shares of company stock valued at $112,525. Insiders own 3.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTR. Nantahala Capital Management LLC raised its stake in Nektar Therapeutics by 90.0% during the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock valued at $7,263,000 after buying an additional 3,700,000 shares during the last quarter. Woodline Partners LP grew its holdings in shares of Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after acquiring an additional 3,242,841 shares during the period. Altium Capital Management LLC increased its position in Nektar Therapeutics by 26,172.0% during the fourth quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $2,790,000 after acquiring an additional 2,988,581 shares during the last quarter. 22NW LP bought a new position in Nektar Therapeutics in the fourth quarter valued at about $2,038,000. Finally, Eventide Asset Management LLC boosted its position in Nektar Therapeutics by 24.8% in the third quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after purchasing an additional 1,870,904 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.